文献速递白血病

MOZ通过调控Hoxa9/Meis1表达对MOZ/MLL融合诱导的白血病发展至关重要

MOZ is critical for the development of MOZ/MLL fusion-induced leukemia through regulation of Hoxa9/Meis1 expression.
PubMed 文献 · Blood Adv · 2022-01-01

本研究探讨内源性MOZ在MLL-AF9、MLL-AF10或MOZ-TIF2融合诱导的急性髓系白血病(AML)中的作用。Moz缺陷的造血干/祖细胞(HSPC)转导MLL-AF10后既不能在甲基纤维素中形成集落也不能在小鼠中诱导AML;转导MLL-AF9后集落和细胞数显著减少;表达MOZ-TIF2的Moz缺陷HSPC体外可形成集落但不能在小鼠中诱导AML。相反,Moz对HOXA9转导细胞的集落形成及HOXA9/MEIS1诱导的AML发展并非必需。Moz缺陷的MLL融合表达细胞中Hoxa9和Meis1表达降低,而Moz缺陷的MOZ-TIF2 AML细胞中仅Meis1(而非Hoxa9)表达降低。向携带MOZ-TIF2的Moz缺陷细胞中引入Meis1可挽救MOZ-TIF2诱导的AML发展;Meis1缺失损害MOZ-TIF2介导的AML发展。Moz缺陷的MOZ-TIF2和MLL-AF9 AML细胞中Meis1位点的活性组蛋白修饰严重减少。结果表明内源性MOZ对MOZ/MLL融合诱导的AML发展至关重要,并维持靶基因位点的活性染色质特征。

要点

  • Moz缺陷的HSPC转导MLL-AF10后既不能在甲基纤维素中形成集落也不能在小鼠中诱导AML。
  • Moz缺陷的HSPC转导MLL-AF9后集落和细胞数显著减少;表达MOZ-TIF2的Moz缺陷HSPC体外可形成集落但不能在小鼠中诱导AML。
  • Moz对HOXA9转导细胞的集落形成及HOXA9和MEIS1诱导的AML发展并非必需。

核心结论

  • 内源性MOZ对MOZ/MLL融合诱导的AML发展至关重要,并维持靶基因位点的活性染色质特征。

研究设计与样本

  • 本研究为实验研究,使用Moz缺陷的造血干/祖细胞(HSPC)转导MLL-AF9、MLL-AF10或MOZ-TIF2融合基因,评估集落形成和小鼠AML诱导能力。

主要发现

  • Moz缺陷的HSPC转导MLL-AF10后既不能在甲基纤维素中形成集落也不能在小鼠中诱导AML。
  • Moz缺陷的HSPC转导MLL-AF9后集落和细胞数显著减少。
  • 表达MOZ-TIF2的Moz缺陷HSPC体外可形成集落但不能在小鼠中诱导AML。
  • Moz对HOXA9转导细胞的集落形成及HOXA9和MEIS1诱导的AML发展并非必需。
  • Moz缺陷的MLL融合表达细胞中Hoxa9和Meis1表达降低,而Moz缺陷的MOZ-TIF2 AML细胞中仅Meis1(而非Hoxa9)表达降低。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Monocytic leukemia zinc finger protein (MOZ, MYST3, or KAT6A) is a MYST-type acetyltransferase involved in chromosomal translocation in acute myelogenous leukemia (AML) and myelodysplastic syndrome. MOZ is established as essential for hematopoiesis; however, the role of MOZ in AML has not been addressed. We propose that MOZ is critical for AML development induced by MLL-AF9, MLL-AF10, or MOZ-TIF2 fusions. Moz-deficient hematopoietic stem/progenitor cells (HSPCs) transduced with an MLL-AF10 fusion gene neither formed colonies in methylcellulose nor induced AML in mice. Moz-deficient HSPCs bearing MLL-AF9 also generated significantly reduced colony and cell numbers. Moz-deficient HSPCs expressing MOZ-TIF2 could form colonies in vitro but could not induce AML in mice. By contrast, Moz was dispensable for colony formation by HOXA9-transduced cells and AML development caused by HOXA9 and MEIS1, suggesting a specific requirement for MOZ in AML induced by MOZ/MLL fusions. Expression of the Hoxa9 and Meis1 genes was decreased in Moz-deficient MLL fusion-expressing cells, while expression of Meis1, but not Hoxa9, was reduced in Moz-deficient MOZ-TIF2 AML cells. AML development induced by MOZ-TIF2 was rescued by introducing Meis1 into Moz-deficient cells carrying MOZ-TIF2. Meis1 deletion impaired MOZ-TIF2-mediated AML development. Active histone modifications were also severely reduced at the Meis1 locus in Moz-deficient MOZ-TIF2 and MLL-AF9 AML cells. These results suggest that endogenous MOZ is critical for MOZ/MLL fusion-induced AML development and maintains active chromatin signatures at target gene loci.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Katsumoto T, Ogawara Y, Yamagata K, et al. MOZ is critical for the development of MOZ/MLL fusion-induced leukemia through regulation of Hoxa9/Meis1 expression. Blood Adv. 2022. PMID: 35947126. doi:10.1182/bloodadvances.2020003490

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。